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Abstract
Background: The purpose of this study was to evaluate the clinicopathologic and ultrasonographic (US)
characteristics and establish an effective scoring system for predicting central lymph node metastasis (CLNM) in
papillary thyroid microcarcinoma (PTMC).
Methods: A total of 498 patients with PTMC who underwent total thyroidectomy or lobectomy with therapeutic
central lymph node dissection (CLND) were enrolled. Univariate and multivariate analyses were performed to find
the independent predictors for CLNM based on clinicopathological and US characteristics. Using the standardized
regression coefficient, a 10-point score system was constructed in line with these independent predictors. Then,
the scoring system was evaluated for the diagnostic value in predicting CLNM.
Results: Tumor location (the lower polo), tumor size (>5 mm), extrathyroidal extension, margin (no well-defined),
display of enlarged lymph node, and contact of >25 % with the adjacent capsule were independent predictors
for CLNM. Verifying the scoring system, a cutoff value of 5 points was found to be the best prediction for CLNM,
the sensitivity and specificity were 64.7 and 80.5 %, respectively, and the positive and negative predictive values
were 77.3 and 69.0 %, respectively.
Conclusions: The points ≤ 5 could be considered as a low risk for CLNM, and the points > 5 could be identified
as a high risk for CLNM. More advanced diagnostic approaches and prophylactic CLND are needed for patients
with the points > 5.
Keywords: Thyroid, Papillary thyroid microcarcinoma, Central lymph node, Central lymph node dissection,
Predictive factor, Scoring system
Background
Papillary thyroid microcarcinoma (PTMC) is defined as
a papillary thyroid carcinoma measuring 1.0 cm or less
in maximal diameter [1]. In the past, most patients with
PTMC were diagnosed from specimens of thyroid removed
for benign diseases, such as Graves’ disease, follicular
adenoma, and multinodular goiter. In recent years, due
to the use of ultrasonography (US) and US-guided fine-
needle aspiration cytology (FNAC), the number of patients
with PTMC has been increasing. Although PTMC is usu-
ally associated with a favorable prognosis, regional lymph
node metastasis (LNM), particularly in the central cervical
compartment, is not uncommon [2]. The central lymph
nodes are considered as the first echelon of lymphatic
metastasis and are the level most frequently involved in
papillary thyroid carcinoma (PTC) [3]. Recent studies
demonstrated that the presence of nodal involvement was
commonly associated with local recurrence and cancer-
specific mortality [4, 5]. Therefore, it is crucial to detect
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the metastatic lymph nodes preoperatively for PTMC, es-
pecially the central lymph nodes.
Nevertheless, the central lymph node metastasis (CLNM)
is frequently diagnosed with microscopic LNM by pathology
(metastatic deposits within a lymph node of less than
2 mm in maximal diameter) which is not easily detected
preoperatively [6, 7]. In clinical node-negative (cN0)
PTMC, the presence of microscopic LNM is frequently de-
tected in surgical specimens, and the prevalence of subclin-
ical CLNM ranges from 30 % to approximately 65 % [2, 8].
Therefore, it is generally agreed that prophylactic central
lymph node dissection (pCLND) should be performed to
remove microscopic LNM because this treatment reduced
local recurrence and cancer-specific mortality. However,
pCLND remains a controversial subject. Zetoune et al. [9]
showed that pCLND did not greatly reduce local recur-
rence in thyroid cancer. Carling et al. [10] demonstrated
that the pCLND would lead to higher rates of hypopara-
thyroidism and recurrent laryngeal nerve injury. Moreover,
a major argument against pCLND was a possibly increased
risk of operative complications and medical cost which
added the burden of patients. A prospective randomized
controlled single-institution study demonstrated that cN0
patients with PTC treated with pCLND showed a similar
outcome. Although one advantage pCLND could reduce
necessity to repeat (131) I treatments, the disadvantage was
a higher prevalence of permanent hypoparathyroidism. Ac-
tually, the different findings on this studies of pCLND could
be explained with the variant percents of CLNM in differ-
ent studies. Almost all clinicians agreed that central lymph
node dissection (CLND) should be done with evidence of
CLNM preoperatively. Hence, how to evaluate accurately
the status of CLNM and choose the CLND as an optimum
operation plan for PTMC are very important in thyroid
operation.
Our study focused on investigating the relationship
between CLNM and the clinicopathological and US
characteristics to find the risk predictors for CLNM in
PTMC. In addition, using the standardized regression
coefficient, we developed a scoring system to identify




We conducted a retrospective case-control study involv-
ing 498 patients who underwent total thyroidectomy or
lobectomy with prophylactic central lymph node at the
First Affiliated Hospital of Wenzhou Medical University
from January 2009 to December 2012. All patients had
no history of thyroid or neck surgery for nonthyroidial
cancer, as well as of neck irradiation. The patients were
divided into the case group (252 patients) and the control
group (246 patients), according to the status of CLNM.
The surgical procedures were performed in the same
operation team of the department of surgical oncology.
The patients’ clinical data were obtained from their
electronic medical records. The research protocol used
in this study was approved by the Ethics Committee of
the First Affiliated Hospital of Wenzhou Medical Uni-
versity, and informed consent was obtained from each
patient.
Parameters analyzed
Clinicopathologic and US characteristics were used to
analyze risk factors of CLNM: a total of 16 selected factors
in Table 1. All pathological diagnoses were made by an ex-
perienced pathologist. Primary tumor size based on US
was measured by the standard of change in echo edge.
When multiple PTMC were found in the specimen, the
largest tumor or the most suspicious dominant nodule
was analyzed. We used the age of 45 years as the cutoff
because of its wide use as a clinical factor for prognosis.
When multiple PTC were found in the specimen, the lar-
gest tumor or the most suspicious dominant nodule was
analyzed. US calcification was defined as the hyperechoic
spots with or without acoustic shadows or as the simple
fine acoustic shadows in ultrasound [11]. ETE was defined
as the tumor perimeter in contact with >25 % of the
thyroid capsule in a malignant lesion or the loss of the
capsule line according to the ultrasound [12]. Tumor
location was classified in four areas (upper, middle,
lower, and isthmus) based on preoperative ultrasono-
graphic findings. LNM was obtained from the final
pathologic reports. All the ultrasound features of the
thyroid nodules were retrospectively reviewed by two
experienced radiologists.
Statistical analysis
Data on normal distribution were expressed as mean ±
standard variation (SD) and were compared with t test.
Categorical variables were expressed as percentage and
were compared with chi-square test or Fisher’s exact test,
as appropriate. Logistic regression analysis was also
performed to estimate the odds ratios (OR) of certain
parameters. Variables with p < 0.05 in the univariate ana-
lysis were progressed to a multivariate analysis using for-
ward stepwise selection. The standardized regression
coefficient was used to quantify the discriminating power
of each factor and to construct a 10-point score system.
The best point for the score system was performed by
receiver-operating characteristic (ROC) curves. All p
values were two sided, and a p value of <0.05 was con-
sidered statistically significant. Statistical analysis was
performed with SPSS software version 19.0 (SPSS, Chicago,
IL, USA).
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Table 1 Baseline characteristics of papillary thyroid microcarcinoma patients stratified by the status of metastatic central lymph
node
Characteristics Total The status of metastatic central lymph node p value
Positive Negative
Total 498 252 246
Sex 0.130
Male (n, %) 143 (28.7 %) 80 (31.7 %) 63 (25.6 %)
Female (n, %) 355 (71.3 %) 172 (68.3 %) 183 (74.4 %)
Age at diagnosis (years) 45.8 ± 9.8 47.2 ± 11.9 0.150
<45 (n, %) 251 (50.4 %) 136 (54.0 %) 115 (46.7 %) 0.107
≥45 (n, %) 247 (49.6 %) 116 (46.0 %) 131 (53.3 %)
Tumor size (mm) 6.8 ± 2.1 5.7 ± 2.6 <0.001
≤5 (n, %) 165 (33.1 %) 51 (20.2 %) 114 (46.3 %) <0.001
>5 (n, %) 333 (66.9 %) 201 (79.8 %) 132 (53.7 %)
Tumor location <0.001
Lower (n, %) 141 (28.3 %) 93 (36.9 %) 48 (19.5 %)
Upper/middle/isthmus (n, %) 357 (71.7 %) 159 (63.1 %) 198 (80.5 %)
No. of nodules 0.416
Single (n, %) 431 (86.5 %) 215 (85.3 %) 216 (87.8 %)
Multiple (n, %) 67 (13.5 %) 37 (14.7 %) 30 (12.2 %)
Hashimoto’s thyroiditis 0.348
Yes (n, %) 87 (17.5 %) 48 (19.0 %) 39 (15.9 %)
No (n, %) 411 (82.5 %) 204 (81.0 %) 207 (84.1 %)
Extrathyroidal extension <0.001
Yes (n, %) 249 (50.0 %) 150 (59.5 %) 99 (40.2 %)
No (n, %) 249 (50.0 %) 102 (40.5 %) 147 (59.8 %)
Vascularization 0.29
Absence (n, %) 435 (87.3 %) 225 (89.3 %) 210 (85.4 %)
External vascularization (n, %) 31 (6.2 %) 15 (6.0 %) 16 (6.5 %)
Internal vascularization (n, %) 32 (6.4 %) 12 (4.8 %) 20 (8.1 %)
Intact capsule 0.548
Yes (n, %) 297 (59.6 %) 147 (58.3 %) 150 (61.0 %)
No (n, %) 201 (40.4 %) 105 (41.7 %) 96 (39.0 %)
Margin <0.001
Well-defined (n, %) 246 (89.8 %) 99 (39.3 %) 147 (59.8 %)
No well-defined (n, %) 252 (50.6 %) 153 (60.7 %) 99 (40.2 %)
Shape 0.280
Regular (n, %) 372 (74.7 %) 183 (72.6 %) 189 (76.8 %)
Irregular (n, %) 126 (25.3 %) 69 (27.4 %) 57 (23.2 %)
Composition 0.188
Solid (n, %) 435 (87.3 %) 225 (89.3 %) 210 (85.4 %)
Cystic or mixed (n, %) 63 (12.7 %) 27 (10.7 %) 36 (14.6 %)
Calcification <0.001
Absence (n, %) 237 (47.6 %) 102 (40.5 %) 135 (54.9 %)
Microcalcification (n, %) 207 (41.6 %) 129 (51.2 %) 78 (31.7 %)
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Results
Univariate analysis
According to the status of metastatic central lymph
node, patients were divided into two groups (the case
group: CLNM positive; the control group: CLNM nega-
tive). Differences in clinicopathological and US features
between two groups were compared in Table 1. Seven
factors were significantly associated with CLNM: display
of enlarged lymph node (p < 0.001), contact of >25 %
with the adjacent capsule (p < 0.001), no well-defined
margin (p < 0.001), tumor size (p < 0.001), tumor location
(p < 0.001), extrathyroidal extension (p < 0.001), and cal-
cification (p < 0.001).
Multivariate analysis
In the multivariate logistic regression, tumor size > 5 mm
(OR 2.986; p < 0.001; 95 % confidence interval (CI) 1.861–
4.790; standardized coefficient regression (Coef) 1.094),
the lower polo (OR 3.568; p < 0.001; 95 % CI 2.211–5.758;
Coef 1.272), extrathyroidal extension (OR 2.631; p < 0.001;
95 % CI 1.720–4.023; Coef 0.967), no well-defined margin
(OR 2.459; p < 0.001; 95 % CI 1.611–3.754; Coef 0.9),
display of metastatic lymph node (OR 3.01; p < 0.001;
95 % CI 1.954–4.634; Coef 1.102), and contact of >25 %
with the adjacent capsule (OR 2.471; p < 0.001; 95 %
CI 1.556–3.922; Coef 0.904) had highly independent
association with central LNM. The relevant informa-
tion is shown in Table 2.
A scoring system
As shown in Table 2, the standardized regression coeffi-
cient is used to quantify the discriminating power (Coef
value) of six predictors and construct a 10-point scoring
system based on their relative predictive weight. The
sum of the points was evaluated to distinguish between
patients with and without CLNM. The mean index
points were 5.71 ± 1.72 in the CLNM-positive group and
3.55 ± 1.95 in the CLNM-negative group, which showed
statistically significant difference (p < 0.001). Using ROC
curve, the area under the ROC curve was 0.791 (Fig. 1).
Then, the cutoff value of 5 was found to be the best
points. The sensitivity and specificity for this scoring
system were 64.7 and 80.5 %, respectively, and the posi-
tive predictive value and negative predictive value were
77.2 and 69.0 %, respectively. When comparing to other
single independent predictors, the scoring system had
more satisfied predictive value (Table 3).
Discussion
In our study, we listed a total of 16 potential predictors
according to the clinicopathological and US features.
Using the univariate analysis, we found that seven predict-
ing factors were significantly associated with the status of
Table 1 Baseline characteristics of papillary thyroid microcarcinoma patients stratified by the status of metastatic central lymph
node (Continued)
Other calcification (n, %) 54 (10.8 %) 21 (8.3 %) 33 (13.4 %)
Taller than wide 0.916
Yes (n, %) 432 (86.7 %) 219 (86.9 %) 213 (86.6 %)
No (n, %) 66 (13.3 %) 33 (13.1 %) 33 (13.4 %)
Display of enlarged lymph nodes <0.001
Yes (n, %) 267 (53.6 %) 165 (65.5 %) 102 (41.5 %)
No (n, %) 231 (46.4 %) 87 (34.5 %) 144 (58.5 %)
Contact of >25 % with the adjacent capsule <0.001
Yes (n, %) 153 (30.7 %) 105 (41.7 %) 48 (19.5 %)
No (n, %) 345 (69.3 %) 147 (58.3 %) 198 (80.5 %)
Table 2 Multivariate analysis (logistic regression) and 10-point scoring system
Characteristic OR 95 % CI p value Coef Score
Size 2.986 1.861–4.790 <0.001 1.094 1.75
Tumor location 3.568 2.211–5.758 <0.001 1.272 2.00
Extrathyroidal extension 2.631 1.720–4.023 <0.001 0.967 1.55
Margin 2.459 1.611–3.754 <0.001 0.900 1.45
Display of enlarged lymph nodes 3.010 1.954–4.634 <0.001 1.102 1.75
Contact of >25 % with the adjacent capsule 2.471 1.556–3.922 <0.001 0.904 1.50
Total 10
Coef standardized coefficient regression, OR odds ratio, 95 % CI 95 % confidence interval
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central LNM. In addition, six independent predictors of
tumor size (>5 mm), tumor location (the lower polo),
extrathyroidal extension, margin (no well-defined), display
of enlarged lymph node, and contact of >25 % with the ad-
jacent capsule for CLNM were confirmed by multivariate
logistic regression analysis.
The incidence of CLNM in PTMC patients has been
reported ranging from 24.1 to 64.1 % [2, 8]. In this study,
we found that the CLNM rate was 50.6 %, which was in
accordance with the incidence rate.
Wada et al. [2] had reported that the location of PTMC
within the thyroid was related to the prevalence of CLNM.
Xu et al. [13] found that a tumor located in the lower third
of the thyroid lobe was a high-risk factor of central lymph
node metastasis. Zhang et al. [14] showed that the patients
with a tumor located in the upper pole of the thyroid lobe
conferred a lower risk for CLNM and a higher risk for lat-
eral cervical metastasis. Similarly, we discovered that
tumor location was an independent predictor for CLNM.
The tumor located in the lower polo of the thyroid has a
higher risk for CLNM, while the tumor located in the
upper third may be a lower risk for CLNM.
Moon et al. [15] certified that PTMC with minimal
ETE more frequently had CLNM than without. He et al.
[16] found that extrathyroidal extension was associated
with subclinical CLNM. Varshney et al. [17] declared
the ETE was associated with the CLNM of PTMC. In
agreement with previous results, we found that thyroid
nodules with ETE were an independent predictive factor
for CLNM.
Generally, no well-defined margin of the thyroid nod-
ule has the strongest risk of malignance. Ito et al. [18]
suggested that no well-defined margin was an important
US feature of biologically aggressive PTMC. Also, we
found that the margin was a highly independent predictor
for CLNM in PTMC.
Traditionally, patients who have PTMC presenting
with palpable lymphadenopathy, by preoperative US,
should have cervical node dissection [2]. PTMC with
ultrasonographical display of metastatic lymph nodes,
especially enlarged lymph nodes, was more likely to
recur in the regional lymph nodes [19]. According to the
univariate and multivariate analyses, we found that
display of enlarged lymph nodes was an independent
predictor for CLNM.
Our study found contact of >25 % with the adjacent
capsule was an independent predicting factor for CLNM.
This US feature is a very important and visualized in
ultrasonic examination. Many literatures suggest that
the presence of contact with the adjacent capsule can
provide a useful predictive information about ETE [20, 21].
According to the above analysis, about the relation between
ETE and CLNM, there was an indirect relationship be-
tween contact of >25 % with the adjacent capsule and
CLNM.
Many literatures confirmed that tumor size was associ-
ated with CLNM. [2, 22]. Many literatures confirmed
Fig 1 Receiver-operating characteristic (ROC) curve for the scoring
system. The area under the ROC curve was 0.791. According to the
ROC curve, a cutoff value of 5 points was found to be best for
distinguishing between patients without and with central LNM. The
sensitivity and specificity were 64.7 and 80.5 %, respectively, and the
positive predictive value and negative predictive value were 77.2
and 69.0 %, respectively. The dotted line represents the 95 % CI
Table 3 The predictive value for the scoring system and independent predictors
Independent predictors Sensitivity (%) Specificity (%) +PV (%) −PV (%)
Size 79.8 46.3 60.4 69.1
Tumor location 36.9 80.5 66.0 55.5
Extrathyroidal extension 59.5 62.6 63.0 59.0
Margin 60.7 59.8 60.7 59.8
Display of enlarged lymph nodes 65.5 58.5 61.8 62.3
Contact of >25 % with the adjacent capsule 41.7 80.5 68.6 57.4
The scoring system 64.7 80.5 77.3 69.0
+PV positive predictive value, −PV negative predictive value
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that tumor size has significant relation with CLNM in
PTMC using the cutoff value of 5 mm [13, 23, 24].
Therefore, in the present study, the tumor size of 5 mm
was regarded as the cutoff value and was proved as an
independent predictor for CLNM.
In this study, calcification was not an independent
factor for central LNM, although it was statistically sig-
nificant on the univariate analysis, which was similar to
two previous reports [20, 25]. Age is known to be an
important prognostic factor for patients with PTC.
However, its predictive value in PTMC was uncertain
[2, 23]. In our study, the gender has no association with
CLNM. Similarly, Liu et al. [23] demonstrate that there
was no relation observed between CLNM and gender in a
meta-analysis. The association between multifocality and
CLNM was still debatable [22, 23, 26]. In our study, no
relevance was found between them. The main reason may
be explained that the incidence rate of multifocality in the
present study is very lower than other studies.
The role of pCLND was still a debate. In our opinion,
those previous studies which analyzed the clinical results
of pCLND had a deficiency. When assessing complica-
tion rates after thyroidectomy, most data are from high-
volume endocrine surgery centers of excellence where
the surgeons have more operation experience and lower
complications rates [10]. In other words, the surgeons’
operation experience on CLND and hospital level had
important influence on survival, postoperative region re-
currence, and complications in PTMC. Hence, the issue
of pCLND is likely to remain so.
If the CLNM could be diagnosed definitively preopera-
tively, the CLND can be easily established. However, in
many patients, CLNM may not show any abnormal find-
ing in preoperative imaging examinations due to their
limitation. To improve the diagnostic accuracy, we used
a combination of clinicopathologic and US characteris-
tics to find six independent predictors for CLNM and
developed a scoring system for predicting CLNM in
PTMC. Using ROC curves, we identified the cutoff value
of 5 points as the best score for detection of CLNM with
a sensitivity of 64.7 %, a specificity of 80.5 %, positive
predictive value of 77.2 %, and negative predictive value
of 69.0 %. The scoring system has obvious advantages in
predicting CLNM in PTMC relative to other single factor.
Moreover, the predictors in this scoring system mainly
come from US characteristics, which is convenient and
feasible for predicting CLNM.
At present, there are many PTC-specific mutations, such
as BRAF V600E and TERT promoter, which can predict
the risk of CLNM in PTMC [27–29]. However, in Asia,
most countries are the developing countries and their med-
ical levels are lower than Europe and the USA. Patients
often cannot afford to take more medical examination
like molecular test. Therefore, in many Asian developing
countries, the scoring system we raised has the advantages
of simplicity and high sensitivity and specificity (compared
with ultrasound) and will be helpful for surgeons to decide
the essential surgical strategy for patients with PTMC, in
particular the subclinical CLNM. In addition, we think
that the use of this scoring system will reduce the surgical
complications and develop the individual therapy for
PTMC.
However, there are several potential limitations in this
study. Firstly, the PTMC has very favorable prognosis
and the follow-up time would be at least 10 years. Our
study did not analyze data from the long-term follow-up
period, such as disease recurrence and disease-free sur-
vival; thus, we cannot directly conclude that the scoring
system can predict the prognosis. Secondly, this study
was conducted in a cross-sectional design, rather than
longitudinal observations. Thirdly, single-center verifica-
tion is not accurate enough. The scoring system needs
multicenter validation to check its predictive value. Fur-
ther investigation with a longer duration is needed.
Conclusions
In conclusion, we first established a scoring system for
predicting CLNM preoperatively in PTMC. The scoring
system of clinicopathological and US characteristics for
the prediction of CLNM can be another alternative diag-
nostic approach when the results of preoperative diagnos-
tic evaluation for CLNM are not adequate or obvious. The
points ≤ 5 could be considered as a low risk for CLNM,
and the points > 5 could be considered as a high risk for
CLNM. More aggressive diagnostic approaches and
prophylactic CLND are needed for the points > 5. There-
fore, the scoring system will be helpful for surgeons to
decide the most suitable surgical strategy for patients
with PTMC, especially the subclinical CLNM.
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